RCT | Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma.

Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH) – Journal of Clinical Oncology (link to abstract – $ for full-text)

Commentary: Adding TACE to Lenvatinib Boosts Survival in Advanced Liver Cancer — In China-based trial, overall survival in first-line improved by 6 months versus lenvatinib alone – MedPage Today (free registration required)